(Q37067643)

18 August 2017

1 reference

title

Inhibiting the renin-angiotensin system with ACE Inhibitors or ARBs after MI. (English)

1 reference

18 August 2017

Maryse Palardy

1

1 reference

18 August 2017

Anique Ducharme

series ordinal

2

1 reference

18 August 2017

Eileen O'Meara

series ordinal

3

1 reference

18 August 2017

publication date

1 December 2007

1 reference

Current heart failure reports

18 August 2017

published in

1 reference

18 August 2017

volume

4

1 reference

18 August 2017

issue

4

1 reference

18 August 2017

page(s)

190-197

1 reference

Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11897-007-0012-7

Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-007-0012-7

Combined angiotensin II receptor antagonism and angiotensin-converting enzyme inhibition further attenuates postinfarction left ventricular remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-007-0012-7

Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-007-0012-7

Angiotensin II type 2 receptor overexpression preserves left ventricular function after myocardial infarction

21 January 2018

1 reference

12 December 2020

The Effect of the Angiotensin-Converting–Enzyme Inhibitor Zofenopril on Mortality and Morbidity after Anterior Myocardial Infarction

1 reference

12 December 2020

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

12 December 2020

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

1 reference

12 December 2020

Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction

1 reference

12 December 2020

Frequency of sudden cardiac death among acute myocardial infarction survivors with optimized medical and revascularization therapy

1 reference

12 December 2020

Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study

1 reference

12 December 2020

GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico

1 reference

12 December 2020

Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group

1 reference

12 December 2020

Angiotensin-converting enzyme inhibitors and angiotensin II type I receptor blockers in the management of congestive heart failure patients: what have we learned from recent clinical trials?

1 reference

12 December 2020

Ventricular enlargement following infarction is a modifiable process

1 reference

12 December 2020

Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling

1 reference

12 December 2020

Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group

1 reference

12 December 2020

Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction

1 reference

12 December 2020

The renin-angiotensin system: a therapeutic target in atrial fibrillation

1 reference

12 December 2020

Transitory reduction in angiotensin AT2 receptor expression levels in postinfarct remodelling in rat myocardium

1 reference

12 December 2020

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

1 reference

12 December 2020

Acute coronary care in the elderly, part II: ST-segment-elevation myocardial infarction: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Ger

1 reference

12 December 2020

Angiotensin II increases human monocyte matrix metalloproteinase-1 through the AT2 receptor and prostaglandin E2: implications for atherosclerotic plaque rupture

1 reference

12 December 2020

Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study.

1 reference

12 December 2020

1 reference

12 December 2020

A systematic review: effect of angiotensin converting enzyme inhibition on left ventricular volumes and ejection fraction in patients with a myocardial infarction and in patients with left ventricular dysfunction

1 reference

12 December 2020

Oral captopril versus placebo among 14,962 patients with suspected acute myocardial infarction: a multicenter, randomized, double-blind, placebo controlled clinical trial. Chinese Cardiac Study (CCS-1) Collaborative Group

1 reference

12 December 2020

Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction

1 reference

12 December 2020

Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial

1 reference

12 December 2020

The pleiotropic effects of angiotensin receptor blockers

1 reference

12 December 2020

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

1 reference

12 December 2020

Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox

1 reference

12 December 2020

Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan

1 reference

12 December 2020

Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease

1 reference

12 December 2020

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

1 reference

12 December 2020

Effect of candesartan on New York Heart Association functional class. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme

1 reference

12 December 2020

Angiotensin II Type 2 Receptor Deficiency Exacerbates Heart Failure and Reduces Survival After Acute Myocardial Infarction in Mice

1 reference

12 December 2020

Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials

1 reference

12 December 2020

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators

1 reference

12 December 2020

ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collabor

1 reference

12 December 2020

Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction

1 reference

12 December 2020

A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group

1 reference

12 December 2020

Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators

1 reference

12 December 2020

Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial

1 reference

12 December 2020

Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II)

1 reference

12 December 2020

Sudden Death in Patients with Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both

1 reference

12 December 2020

Gender differences in treatment of heart failure and acute myocardial infarction: a question of quality or epidemiology?

1 reference

12 December 2020

Left ventricular remodeling after anterior wall acute myocardial infarction in modern clinical practice (from the REmodelage VEntriculaire [REVE] study group).

1 reference

12 December 2020

The occurrence and prognostic significance of atrial fibrillation/-flutter following acute myocardial infarction. TRACE Study group. TRAndolapril Cardiac Evalution

1 reference

12 December 2020

ACC/AHA Guideline Update for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction--2002: Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice G

1 reference

12 December 2020

Effect of angiotensin-converting enzyme inhibition on functional class in patients with left ventricular systolic dysfunction--a meta-analysis

1 reference

12 December 2020

Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).

1 reference

12 December 2020

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

1 reference

12 December 2020

Hemodynamic benefits and prolonged survival with long-term captopril therapy in rats with myocardial infarction and heart failure.

1 reference

12 December 2020

Renal damage after myocardial infarction is prevented by renin-angiotensin-aldosterone-system intervention

1 reference

12 December 2020

Angiotensin II type 2 receptor mediates programmed cell death

1 reference

12 December 2020

Chymase-dependent angiotensin II formation in human vascular tissue

1 reference

12 December 2020

Left ventricular remodeling after acute myocardial infarction

1 reference

12 December 2020

Renin-angiotensin system and cardiovascular risk

1 reference

12 December 2020

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions

1 reference

12 December 2020

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

1 reference

12 December 2020

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

1 reference

12 December 2020

Progressive ventricular remodeling in rat with myocardial infarction

1 reference

12 December 2020

ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise th

1 reference

12 December 2020

Influence of proteinuria on cardiovascular risk and response to angiotensin-converting enzyme inhibition after myocardial infarction

1 reference

12 December 2020

Effects of combination of angiotensin-converting enzyme inhibitor and angiotensin receptor antagonist on inflammatory cellular infiltration and myocardial interstitial fibrosis after acute myocardial infarction

1 reference

12 December 2020

10.1007/S11897-007-0012-7

Identifiers

DOI

1 reference

18 August 2017

1 reference